Comment on “Predictive Effects of the Lactate/Albumin Ratio on Neurological Outcomes in Patients After Out-of-Hospital Cardiac Arrest”

IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL
Shyam Sundar Sah, Abhishek Kumbhalwar
{"title":"Comment on “Predictive Effects of the Lactate/Albumin Ratio on Neurological Outcomes in Patients After Out-of-Hospital Cardiac Arrest”","authors":"Shyam Sundar Sah,&nbsp;Abhishek Kumbhalwar","doi":"10.1002/ams2.70102","DOIUrl":null,"url":null,"abstract":"<p>We read with great interest Nakada et al.'s large, nationwide analysis of the lactate/albumin ratio (LAR) measured on hospital arrival and its association with neurological outcomes after out-of-hospital cardiac arrest (OHCA) [<span>1</span>]. The authors should be commended for leveraging the Japanese Association for Acute Medicine (JAAM-OHCA) registry to test a biologically plausible composite biomarker across a broad population (<i>n</i> = 28,098) and for performing subgroup analyses addressing admission status and receipt of active post-resuscitation therapies. Their finding that LAR improved discrimination over lactate or albumin alone and modestly enhanced a reference model is relevant to early risk stratification in a condition where timely prognostic information is valuable. Nevertheless, several issues temper the translational value of the results.</p><p>First, the timing and selection for blood sampling were not standardized and depended on clinicians' discretion. This introduces selection bias, as patients undergoing longer evaluation or surviving slightly longer were more likely to have albumin measured, while albumin assays typically require more processing time than lactate [<span>2</span>]. Such variability may exaggerate LAR's prognostic value and likely contributed to the diminished incremental effect observed in admitted patients. Standardized, early sampling protocols would strengthen future validation.</p><p>Second, although discrimination metrics such as area under the curve (AUC), integrated discrimination improvement (IDI), and net reclassification improvement (NRI) were reported, the clinical impact remains unclear. An AUC of 0.83 is encouraging, yet the absolute gain over the reference model and its effect on decision thresholds were not quantified. Reporting predictive values, calibration, and net clinical benefit would clarify whether LAR provides practical guidance rather than only statistical improvement [<span>3</span>].</p><p>Third, residual confounding is possible. Albumin levels are influenced by chronic liver disease, nutritional status, and fluid balance [<span>4</span>], while lactate is affected by sepsis, epinephrine dosing, and prehospital variables [<span>5</span>]. These were not accounted for in the models, which may bias associations. Adjustment for comorbidity burden or sensitivity analyses excluding patients with advanced chronic disease would improve robustness.</p><p>Finally, operational considerations limit generalizability. Japan's emergency medical service (EMS) system, where field termination is rare, shapes the case mix and may not reflect other settings. External prospective validation with standardized sampling and serial biomarker kinetics will be essential to confirm clinical applicability.</p><p>In conclusion, Nakada et al. provide important large-scale evidence that LAR is associated with neurological outcomes after OHCA and improves prognostic discrimination beyond single biomarkers. Future studies should focus on standardized measurement, broader adjustment for confounders, and clinical utility analyses to establish whether LAR can serve as a practical adjunct in early post-resuscitation care.</p><p>Generative <b>AI</b> Use Statement: Generative AI tools, including Paperpal and ChatGPT-4o, were utilized solely for language, grammar, and stylistic refinement. These tools had no role in the conceptualization, data analysis, interpretation of results, or substantive content development of this manuscript. All intellectual contributions, data analysis, and scientific interpretations remain the sole work of the authors. The final content was critically reviewed and edited to ensure accuracy and originality. The authors take full responsibility for the accuracy, originality, and integrity of the work presented.</p><p>The authors have nothing to report.</p><p>The authors declare no conflicts of interest.</p><p>This article is linked to Nakada et al. paper “Predictive effects of the lactate/albumin ratio on neurological outcomes in patients after out-of-hospital cardiac arrest”. To view this article, visit https://doi.org/10.1002/ams2.70082.</p>","PeriodicalId":7196,"journal":{"name":"Acute Medicine & Surgery","volume":"12 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ams2.70102","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acute Medicine & Surgery","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ams2.70102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

We read with great interest Nakada et al.'s large, nationwide analysis of the lactate/albumin ratio (LAR) measured on hospital arrival and its association with neurological outcomes after out-of-hospital cardiac arrest (OHCA) [1]. The authors should be commended for leveraging the Japanese Association for Acute Medicine (JAAM-OHCA) registry to test a biologically plausible composite biomarker across a broad population (n = 28,098) and for performing subgroup analyses addressing admission status and receipt of active post-resuscitation therapies. Their finding that LAR improved discrimination over lactate or albumin alone and modestly enhanced a reference model is relevant to early risk stratification in a condition where timely prognostic information is valuable. Nevertheless, several issues temper the translational value of the results.

First, the timing and selection for blood sampling were not standardized and depended on clinicians' discretion. This introduces selection bias, as patients undergoing longer evaluation or surviving slightly longer were more likely to have albumin measured, while albumin assays typically require more processing time than lactate [2]. Such variability may exaggerate LAR's prognostic value and likely contributed to the diminished incremental effect observed in admitted patients. Standardized, early sampling protocols would strengthen future validation.

Second, although discrimination metrics such as area under the curve (AUC), integrated discrimination improvement (IDI), and net reclassification improvement (NRI) were reported, the clinical impact remains unclear. An AUC of 0.83 is encouraging, yet the absolute gain over the reference model and its effect on decision thresholds were not quantified. Reporting predictive values, calibration, and net clinical benefit would clarify whether LAR provides practical guidance rather than only statistical improvement [3].

Third, residual confounding is possible. Albumin levels are influenced by chronic liver disease, nutritional status, and fluid balance [4], while lactate is affected by sepsis, epinephrine dosing, and prehospital variables [5]. These were not accounted for in the models, which may bias associations. Adjustment for comorbidity burden or sensitivity analyses excluding patients with advanced chronic disease would improve robustness.

Finally, operational considerations limit generalizability. Japan's emergency medical service (EMS) system, where field termination is rare, shapes the case mix and may not reflect other settings. External prospective validation with standardized sampling and serial biomarker kinetics will be essential to confirm clinical applicability.

In conclusion, Nakada et al. provide important large-scale evidence that LAR is associated with neurological outcomes after OHCA and improves prognostic discrimination beyond single biomarkers. Future studies should focus on standardized measurement, broader adjustment for confounders, and clinical utility analyses to establish whether LAR can serve as a practical adjunct in early post-resuscitation care.

Generative AI Use Statement: Generative AI tools, including Paperpal and ChatGPT-4o, were utilized solely for language, grammar, and stylistic refinement. These tools had no role in the conceptualization, data analysis, interpretation of results, or substantive content development of this manuscript. All intellectual contributions, data analysis, and scientific interpretations remain the sole work of the authors. The final content was critically reviewed and edited to ensure accuracy and originality. The authors take full responsibility for the accuracy, originality, and integrity of the work presented.

The authors have nothing to report.

The authors declare no conflicts of interest.

This article is linked to Nakada et al. paper “Predictive effects of the lactate/albumin ratio on neurological outcomes in patients after out-of-hospital cardiac arrest”. To view this article, visit https://doi.org/10.1002/ams2.70082.

对“乳酸/白蛋白比值对院外心脏骤停患者神经预后的预测作用”的评论
我们非常感兴趣地阅读了Nakada等人的大型全国性分析,分析了医院到达时测量的乳酸/白蛋白比率(LAR)及其与院外心脏骤停(OHCA) bbb后神经系统预后的关系。作者利用日本急性医学协会(JAAM-OHCA)登记在广泛人群(n = 28,098)中测试生物学上合理的复合生物标志物,并对入院状况和积极复苏后治疗的接受情况进行亚组分析,应该受到赞扬。他们发现LAR改善了对单独乳酸蛋白或白蛋白的区分,并适度增强了参考模型,这与及时预后信息有价值的情况下的早期风险分层有关。然而,有几个问题影响了研究结果的翻译价值。首先,采血时间和选择不规范,取决于临床医生的自由裁量权。这引入了选择偏倚,因为接受更长评估或存活时间稍长的患者更有可能测量白蛋白,而白蛋白测定通常需要比乳酸bbb更多的处理时间。这种可变性可能会夸大LAR的预后价值,并可能导致在住院患者中观察到的增量效应减弱。标准化的早期抽样方案将加强未来的验证。其次,尽管诸如曲线下面积(AUC)、综合判别改善(IDI)和净再分类改善(NRI)等判别指标已被报道,但临床影响仍不清楚。AUC为0.83是令人鼓舞的,但是对参考模型的绝对增益及其对决策阈值的影响没有量化。报告预测值、校准和临床净收益将澄清LAR是否提供了实际指导,而不仅仅是统计改善bbb。第三,残留混淆是可能的。白蛋白水平受慢性肝病、营养状况和体液平衡[5]的影响,而乳酸水平受败血症、肾上腺素剂量和院前变量[5]的影响。在模型中没有考虑到这些因素,这可能会使关联产生偏差。调整合并症负担或排除晚期慢性疾病患者的敏感性分析将提高稳健性。最后,操作方面的考虑限制了通用性。日本的紧急医疗服务(EMS)系统很少进行现场终止,这影响了病例组合,可能无法反映其他情况。通过标准化取样和一系列生物标志物动力学进行外部前瞻性验证对于确认临床适用性至关重要。总之,Nakada等人提供了重要的大规模证据,证明LAR与OHCA后的神经预后相关,并改善了单一生物标志物之外的预后区分。未来的研究应侧重于标准化测量、更广泛的混杂因素调整和临床效用分析,以确定LAR是否可以作为早期复苏后护理的实用辅助手段。生成式AI使用说明:生成式AI工具,包括Paperpal和chatgpt - 40,仅用于语言,语法和风格改进。这些工具在本文的概念化、数据分析、结果解释或实质性内容开发中没有作用。所有的智力贡献,数据分析和科学解释仍然是作者的唯一工作。最后的内容经过严格审查和编辑,以确保准确性和原创性。作者对文章的准确性、原创性和完整性承担全部责任。作者没有什么可报告的。作者声明无利益冲突。这篇文章与Nakada等人的论文“乳酸/白蛋白比值对院外心脏骤停患者神经预后的预测作用”相关联。要查看本文,请访问https://doi.org/10.1002/ams2.70082。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acute Medicine & Surgery
Acute Medicine & Surgery MEDICINE, GENERAL & INTERNAL-
自引率
12.50%
发文量
87
审稿时长
53 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书